Sirolimus Concept

subject area of

• A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041)  Academic Article
• A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas  Conference Paper
• A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors  Academic Article
• Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer  Academic Article
• An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy  Academic Article
• CCI-779 Wyeth.  Academic Article
• Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus  Academic Article
• Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer  Academic Article
• Combined mTOR Inhibition and OX40 Agonism Enhances CD8+ T Cell Memory and Protective Immunity Produced by Recombinant Adenovirus Vaccines  Academic Article
• Combined mTOR inhibition and OX40 agonism enhances CD8(+) T cell memory and protective immunity produced by recombinant adenovirus vaccines.  Academic Article
• Defining vascular anomaly phenotypes in children based on a systematic literature search: A critical step in developing a single severity score for interventional clinical trials  Academic Article
• Drug evaluation: AP-23573--an mTOR inhibitor for the treatment of cancer.  Academic Article
• E2F7 promotes mammalian target of rapamycin inhibitor resistance in hepatocellular carcinoma after liver transplantation  Academic Article
• Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2  Academic Article
• Effect of FKBP65, a putative elastin chaperone, on the coacervation of tropoelastin in vitro  Academic Article
• Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup analysis from the BOLERO-2 study  Academic Article
• Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis  Academic Article
• Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer  Academic Article
• Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2  Academic Article
• Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancer  Academic Article
• Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Disease  Academic Article
• Glucose transporter expression in L6 muscle cells: Regulation through insulin- and stress-activated pathways  Academic Article
• Health-related quality of life and disease symptoms in postmenopausal women with HR⁺, HER2⁻advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy  Academic Article
• Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial  Academic Article
• Health-related quality-of-life outcomes of sirolimus-treated kidney transplant patients after elimination of cyclosporine A: results of a 2-year randomized clinical trial1  Conference Paper
• Immunosuppression without calcineurin inhibition: optimization of renal function in expanded criteria donor renal transplantation  Academic Article
• Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2  Academic Article
• Intragraft CD11b+IDO+ Cells Mediate Cardiac Allograft Tolerance by ECDI-Fixed Donor Splenocyte Infusions  Academic Article
• Long-term benefit using DES in STEMI patients.  Academic Article
• Mechanisms coordinating ribosomal protein gene transcription in response to stress  Academic Article
• Metastatic renal cell cancer treatments: An indirect comparison meta-analysis  Academic Article
• Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis  Academic Article
• Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management  Academic Article
• Opportunities for enhancing the care of older patients with ST-elevation myocardial infarction presenting for primary percutaneous coronary intervention: Rationale and design of the SAFE-STEMI for Seniors trial  Academic Article
• PCI with drug-eluting stents ≤ 12 months before surgery was linked to increased MI and cardiac death after surgery  Academic Article
• Paclitaxel Versus Sirolimus Stents in Diabetic and Nondiabetic Patients  Academic Article
• Phase I study of vinblastine and temsirolimus in pediatric patients with recurrent or refractory solid tumors: Canadian Cancer Trials Group Study IND.218  Academic Article
• Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group  Academic Article
• Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer  Academic Article
• Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199)  Academic Article
• Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163  Conference Paper
• Rapamycin does not prevent increases in myofibrillar or mitochondrial protein synthesis following endurance exercise  Academic Article
• Rapamycin has a beneficial effect on controlling epilepsy in children with tuberous sclerosis complex: results of 7 children from a cohort of 86  Academic Article
• Rapamycin inhibits transforming growth factor β-induced peritoneal angiogenesis by blocking the secondary hypoxic response  Academic Article
• Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma  Academic Article
• Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptor–Positive Breast Cancer in BOLERO-2  Academic Article
• Sirolimus Therapy after Early Cyclosporine Withdrawal Reduces the Risk for Cancer in Adult Renal Transplantation  Academic Article
• Sirolimus and low-dose tacrolimus with antibody induction in kidney transplantation: preliminary results of a pilot study  Conference Paper
• Sirolimus and mTORC1: centre stage in the story of what makes muscles bigger?  Academic Article
• Sirolimus is not always responsible for new-onset proteinuria after conversion for chronic allograft nephropathy  Academic Article
• Sirolimus-Based Therapy Following Early Cyclosporine Withdrawal Provides Significantly Improved Renal Histology and Function at 3 Years  Academic Article
• Surgical biology for the clinician: vascular effects of immunosuppression.  Academic Article
• Targeted therapy for metastatic renal cell carcinoma  Academic Article
• Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179)  Academic Article
• The mTORC Pathway in the Antiphospholipid Syndrome  Academic Article
• Very Late Stent Fracture Associated With a Sirolimus-eluting Stent  Academic Article